We use cookies to give you the best experience possible with our website and to improve our communication with you. We consider your selection and will only use the data you have approved us to gather.

These cookies help making a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.

These cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously. With this information we can constantly improve the experience we offer on our website.

These cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.

The key to success

Geistlich Pharma is committed to its own research and development. Accordingly, the company invests in skilled professionals and technologies, and it nurtures international cooperation. Geistlich is characterized by its passion for science. That too is reflected largely in its research and development. Swiss and international professionals and specialists alike dedicate themselves to the shared goal of tirelessly improving regenerative medicine. This goal is built on a thorough understanding of the biology of matrix structures.

“When it comes to quality, we don’t compromise.”
Patrick Häuptli, Director Quality Assurance


Swiss quality under one roof

It is important to Geistlich that all research and development is done in-house and that it meets its high standards of Swiss quality. A wide spectrum of in-house research takes place – from biochemistry to cell biology, and material research to research analytics. When research is carried out at Geistlich, it is done with the precept of supporting the body’s own regenerative processes with biological products. The result of this commitment is the regeneration of natural tissue with the interaction between product and body. Before launching a product, Geistlich always endeavors to prove its clinical efficacy in a watertight manner.


“You’re either a pioneer or you remain static.”
Dr. Mark Spilker, CSO Geistlich Pharma


Product efficacy demonstrated in about 1,400 scientific publications   

Decades of experience with biomaterials and pioneering work achieved are documented in meaningful scientific evidence. The efficacy of Geistlich’s biomaterials is documented in about 1,400 scientific publications    – when it comes to the safety and quality of its products, Geistlich doesn’t compromise. To learn from the best and gain valuable expertise, the company networks with renowned international experts, university partners and esteemed clinical practitioners. New treatment concepts and products are born from the exchanges between this network of expertise. Geistlich places great importance on training medical professionals. The strive for excellence means that a Geistlich biomaterial is used every 15 seconds around the world.


Dr. Mirjam Kessler
Director Corporate Communications